Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire
441 Leser
Artikel bewerten:
(1)

Nasdaq Nordic: Nasdaq Stockholm Welcomes Xbrane Biopharma AB to The Main Market

Stockholm, September 23, 2019 - Nasdaq (Nasdaq: NDAQ) announces that the
trading in Xbrane Biopharma AB's shares (short name: XBRANE) will commence
today on the Nasdaq Stockholm main market. Xbrane Biopharma AB belongs to the
healthcare sector and is the 40th company to be admitted to trading on Nasdaq's
Nordic markets* in 2019. Xbrane Biopharma was previously listed on the Nasdaq
First North Growth Market. 

Xbrane Biopharma is a Swedish biopharmaceutical company that develops
biosimilars, in order to provide cost efficient medicines to patient
populations that do not have access to affordable treatments. Due to the
current state of the market and inflated prices for pharmaceutical drugs, there
is a large unmet medical need as patients cannot afford medications for their
diseases. Xbrane Biopharma's leading product, Xlucane, is in phase III with a
targeted launch in 2022. The product is developed in partnership with STADA
Arzneimittel. Xbrane Biopharma has 36 employees and is headquartered in Solna,
Sweden, where it also has its pilot scale development facility. 

"Our switch to the Nasdaq Stockholm main market is a key milestone for us,"
said Martin Åmark, CEO of Xbrane Biopharma. "This will further increase the
awareness of Xbrane Biopharma, strengthen the company's brand and visibility,
while confirming the progress and maturity of our company. It will also allow
us to fully leverage our patented platform technology to develop cost efficient
medicines and significantly increase treatment accessibility to patients in
need. Furthermore, the admission to trading on Nasdaq Stockholm is expected to
satisfy the interest of institutional investors and give our company greater
access to the Swedish and international capital markets." 

"We welcome Xbrane Biopharma to the Nasdaq Stockholm main market," said Adam
Kostyál, SVP and Head of European Listings, Nasdaq. "Xbrane Biopharma will join
our strong and vibrant health care sector, and we look forward to supporting
them on their continued journey on the Nasdaq Stockholm main market." 

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki,
Nasdaq Iceland and Nasdaq Stockholm 

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing,
exchange technology, listing, information and public company services. Through
its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize
and execute their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global capital
markets. As the creator of the world's first electronic stock market, its
technology powers more than 100 marketplaces in 50 countries. Nasdaq is home to
over 4,000 total listings with a market value of approximately $14 trillion. To
learn more, visit business.nasdaq.com. 



Nasdaq Media Contact

Erik Granström

+46 73 449 78 07

erik.granstrom@nasdaq.com
Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2019 GlobeNewswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.